Introduction: The renin angiotensin system (RAS) is closely related to the cardiovascular system, body fluid regulation and homeostasis. Materials and methods: Despite common therapeutic methods, stem cell/progenitor cell therapy is daily increasing as a term of regenerative medicine. RAS and its pharmacological inhibitors are not only involved in physiological and pathological aspects of the cardiovascular system, but also affect the different stages of stem cell proliferation, differentiation and function, via interfering cell signaling pathways. Results: This study reviews the new role of RAS, in particular Ang II distinct from other common roles, by considering its regulating impact on the different signaling pathways involved in the cardiac and endothelial tissue, as well as in stem cell transplantation. Conclusions: This review focuses on the impact of stem cell therapy on the cardiovascular system, the role of RAS in stem cell differentiation, and the role of RAS inhibition in cardiac stem cell growth and development.
Introduction
The classical renin-angiotensin system (RAS) is a hormonal system which is commonly associated with blood pressure and body fluid homeostasis regulation. 1 Renin is an enzyme produced in the kidney that metabolizes angiotensinogen to angiotensin I (Ang I), which is then converted to angiotensin II (Ang II) by angiotensin converting enzyme (ACE). Ang II, the major effector peptide of the RAS, acts through its receptors, mainly Angiotensin II receptor Type 1 (AT1) and Angiotensin II receptor Type 2 (AT2) 2 ; however, most cardiovascular effects of Ang II are conveyed by the AT1, which not only includes vasoconstriction, vascular cell hypertrophy, hyperplasia and sodium retention. In addition, AT1 receptor stimulation results in reactive oxygen species (ROS) formation, with inflammatory and thrombotic effects.
AT1, as a G protein-coupled receptor, induces tyrosine kinase phosphorylation. This phosphorylation turns on several downstream signals, like Ras/Rho, mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) and translocation of MAPK into the nucleus. 3 Aside, Ang II has the potential to activate the Janus kinase and signal transducer, and the activator of transcription (JAK/STAT) signaling pathway, which is associated in part with acute myocardial ischemia. Furthermore, Ang II stimulates early growth-response genes and myocardial hypertrophy. Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor beta (TGF-β) and insulin-like growth factor 1 (IGF-1) gene expression are all increased, subsequent to Ang II activation. 4 The stimulation of ROS production occurs through the activation of nicotinamide adenine dinucleotide phosphateoxidase (NADPH) oxidase, as a downstream of RAS signaling pathway in different cell types. 5 A review of the literature indicates that the AT2 receptor exerts opposite effects to those of the AT1 receptor; and it is over-expressed, especially during pathological circumstances in different organs, 6 by representing protective effects in end organ damage, such as in stroke and in kidney dysfunction. 7 The stimulation of the AT2 receptor improves cardiac function after myocardial infarction, through anti-inflammatory and anti-oxidant mechanisms, and by more favorable scar remodeling. [8] [9] [10] Moreover, AT2 receptor activation inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity; and subsequently, the synthesis of pro-inflammatory cytokines. 11 AT2 receptor agonists may potentially offer beneficial effects, to improve the regenerative potential of stem or progenitor cells that were derived from patients with cardiovascular disease. 12 The existence of RAS components in different organs and tissues, especially in renal and cardiovascular diseases, 13 suggests the presence of local RAS in addition to the circulating common RAS. [13] [14] [15] Local RAS participates in various cell functions, such as: cell proliferation, cellular organogenesis and pro-inflammatory actions. 16 Angiotensin mRNA, protein and Ang II are detected in the vascular wall, as components of the local RAS.
Ang II increases vascular tone and blood pressure, by binding to its own receptor. Besides, Ang II has inflammatory effects on the vasculature by inducing integrins, adhesion molecules, cytokines and growth mediators through the activation of the transcription factors and ROS formation. 17 The AT1 receptor activation in vessel wall results in ROS formation and in nitric oxide (NO) inactivation, which is accompanied within the endothelial dysfunction. 18 The heart is itself capable of Ang II production, and cardiac myocytes and fibroblasts express the AT1 receptor. Cardiac hypertrophy and fibrosis occur via the activation of the AT1 receptor, but not the AT2 receptor. 19 Ang II uses mediators, such as endothelin and norepinephrine, in cardiomyocyte growth; and it induces cardiac hypertrophy, via the stimulation of ROS formation. 20 Cell-based therapies hold the promise to treat degenerative diseases, cancer and repair of damaged organs for which there are currently no or limited therapeutic options. 21 Recently, increased developments and research in the stem cell field have attempted to increase stem cell therapy efficacy. [22] [23] [24] Besides the role of RAS in stem cell differentiation, its role in function and proliferation makes it an attractive research field in regenerative medicine. 25 This review attempts to discuss the effects of Ang II in stem cell therapy, particularly in the cardiovascular system.
Stem cell therapy in the cardiovascular system
Despite extensive and modern methods of pharmacological and surgical treatment of cardiovascular disease (CVD), the CVDs are among the leading causes of death in developed countries. Stem cell therapy has been on the frontier in preventing and treating many diseases, including CVDs with a promising future. [26] [27] [28] Mesenchymal stem cells (MSC), which are multipotent cells, are predominantly found in bone marrow and adipose tissue and can differentiate into various cell types, including cardiomyocytes and endothelial cells. 29 Because of the simple isolation of MSCs, their highly immuneprivileged and angiogenesis-inducing properties, MSCs seem to be appropriate candidates for stem cell therapy. 30 MSCs have shown helpful effects in CVDs, including myocardial infarction (MI), arrhythmias, coronary artery disease (CAD) and atherosclerosis. 31 Moreover, these cells exert paracrine effects such as neoangiogenesis, reducing myocardial fibrosis and remodeling. 32 The injection of cell-free medium containing the secreted factors of MSCs has improved myocardial regeneration after MI. Another paracrine effect of MSCs as an effective approach for re-vascularization is the improvement of microvascular remodeling through the decreasing of oxidative stress. 33 These paracrine effects may act via the suppression of the TGF-β/Smad2 signaling pathway; and behave as an anti-remodeling and endothelial function-improving factor in pulmonary hypertension. 34 In the rat pulmonary hypertension model, MSCs show superiority regarding the lowering of blood pressure and thus, ventricular overload; hence, MSC transplantation in chronic lung disease with pulmonary hypertension has pointed toward a new therapeutic intervention. 35 In atherosclerotic renal artery stenosis of swine, MSCs that were given concomitant with percutaneous trans-luminal renal angioplasty decrease inflammation, fibrinogenesis and vascular remodeling. 36 The anti-inflammatory and immunosuppressive effects of MSC transplantation have influenced arteriosclerosis positively. 37 MSCs have the ability to recognize inflammation lesions; and Ang II effects the migration and homing of these cells to the site of injury. 38 Dysregulation of the RAS subsides the angiogenic therapeutic potential of these cells. 39 Embryonic stem cells (ESCs) are another group of pluripotent cells that are able to differentiate into cardiomyocytes and endothelial cells, which have been mentioned as a source of regeneration therapy. 40 ESC-derived endothelial cells with therapeutic efficacy not only commence angiogenesis, but also improve the functional properties of the heart. 41, 42 In vitro studies indicate that human ESCderived cardiomyocyte proliferation happens through the PI3/Akt signaling pathway. 43 RAS modulates the PI3-K/ Akt activation; and inhibition of RAS increases Akt phosphorylation, 44 which may affect the proliferation of ESCs. Another important, noteworthy issue about these cells is their good survival rate after transplantation. 45 The concept of postnatal vasculogenesis was introduced within the identification of the circulating endothelial progenitor cell (EPC). 46 EPCs could originate from hematopoietic stem cells (HSCs) or MSCs. 47, 48 In addition, the EPCs existing in the adventitial layer of vessels are able to differentiate into adult endothelial cells. 49 Vascular damage, ischemia and even physical exercise induce the recruitment of circulating EPCs, resulting in neovascularization and restoration of endothelial function. 50, 51 Clinical trial studies have shown an improvement of perfusion in the myocardium by EPC transplantation. 52, 53 Regarding EPCs mobilization, several mechanisms have previously been suggested. As such, it was noticed that ischemic injuries release angiogenic factors like VEGF, and activate MAPK or the RAS signaling pathways. 25, 54 Although stem cell transplantation looks safe, it may possess serious complications, such as increasing the size of the atherosclerotic area. Labeled bone marrow-derived MSCs have been detected after balloon injury in hyperlipidemic rat arteries, leading to negative remodeling and in situ calcification. 55 Detection of the non-host origin of tumors after stem cell transplantation indicates their tumorigenic potential. 56 Unwanted differentiation is another risk factor that may occur in regenerative medicine; and it was reported as MSC differentiation into unwanted mesenchymal cell types, such as osteocytes and adipocytes. 57 Hence, improving the aforementioned remedies and the current knowledge on the mechanism of stem cell therapy should be considered, as well. Table 1 represents the stem cell types that are discussed in this review. The modulation of progenitor cells and the regulation of their differentiation; and the mobilization mechanism of impaired angiogenesis disease, seem quite remarkable. According to the well-known role of Ang II in CVDs and the RAS intervention in the function, the proliferation and differentiation of stem cell/progenitor cells promote our understanding of such processes.
The role of RAS in stem cells
Recent research has attempted to improve stem cell functionality, in order to make stem cells promising candidates for tissue transplantation in different kinds of disease or lost/damaged organs. Emerging studies have examined the RAS influence on stem cell growth, proliferation and function. 58 Ang II receptor stimulation gives rise to the proliferation of various progenitor cells, such as mouse bone marrow-derived stem cells or human cord blood cells. Lowering the effect of the RAS has a close relationship with anemia, via suppression of bone marrow-derived hematopoietic cell production. 59 The role of Ang II in the differentiation of stem cell/progenitor cells has been proven in many studies. 60 The existence of AT receptors in differentiated, but not in undifferentiated cells, suggests the idea that Ang II can also regulate stem cells' differentiation. 61 Besides the paracrine effects of the RAS direct stem cell/progenitor cells to differentiate into special cells such as SMCs or adipocytes. 62, 63 Numerous studies have implicated the role of RAS in the regulation of bone marrow-derived stem cells, especially focusing on hematopoiesis and erythropoiesis in an autocrine/paracrine manner. 64 The mitogenic function of Ang II results in CD34+ hematopoietic progenitor cell proliferation of early erythroid progenitors, through increasing the number of burst-forming units in erythroid colonies. 65 Also, AT1 receptor activation stimulates erythroblast proliferation and hemangioblast differentiation, while inhibition of the RAS function diminishes erythropoiesis. 66 Other components of the RAS are also associated. ACE (also known as CD143) marks hematopoietic stem cells in human embryonic, fetal and adult hematopoietic tissues. 67 In addition, ACE and the RAS directly regulate hemangioblast expansion and differentiation. 68 The time of exposure to Ang II is, of course, noticeable in determining the RAS effect on stem cell differentiation. Although acute Ang II signaling mediates proliferative effects on SCs positively, long-term treatment with Ang II increases NADPH oxidase activity and thus, elevated ROS production. 59, 69 Expression of Ang II receptors in rat hippocampal neural stem cells (NSCs) leads to the proliferation of related stem cells. 70 As in NSCs, NADPH oxidase-induced superoxide turns on the stem cells' proliferation. 71 Ang II can also induce inflammatory responses, through stimulation of ROS generation. 72 Ang II dose-dependently increases the secretion of inflammatory cytokines such as TNF-α, IL-1β and IL-6 in bone marrowderived MSCs. 73 Furthermore, the local RAS paracrine activity regulates several signaling pathways in the context of homing and recognizing target tissue for stem cell transplantation. 74 Stem cells that engraft functionality and differentiations, as well as the embryonic stage differentiation of the progenitor cells, are affected by the RAS. 75 In addition to influencing cellular function and structure in the adult pancreas, local RAS has a major effect on pancreatic stem cells/ progenitor cells (PPC) during development. 1 Pancreatic islet RAS regulates PPC differentiation, after transplantation of MSCs, and thereby enables beneficial outcomes to accomplish permanent normal blood glucose levels in patients with Type 1 diabetes. 76 Pharmacotherapy by means of the RAS may also be helpful in diabetic, atherosclerotic and hypertensive patients, who are associated with EPC dysfunction and impaired skeletal muscle perfusion. Ang II infusion was shown to increase circulating EPCs by impacting bone marrow-derived EPC differentiation. 39 
The role of RAS in cardiac stem cells
In addition to influencing in different kinds of stem cells, the RAS effect on CV-related stem cell transplantation has largely been investigated regarding the intracellular signaling pathway of Ang II (Figure1). Induced pluripotent stem cells (iPSCs) are a type of cells that are artificially derived from adult differentiated non-pluripotent somatic cells. Despite different origins, these cells resemble ESCs in their growth and gene expression characteristics. 77 Besides, iPSCs have the ability to express Ang II receptors. Ang II induces the proliferation of pluripotent cells and instigates their differentiation into MSCs. 66 Ang II can activate the intracellular signaling cascades via anion superoxide production, which leads to the proliferation of stem cells. 78 Treating pluripotent stem cells with Ang II and Tempol (ROS production inhibitor) suppresses the proliferation of cells and DNA synthesis that indicates a role in the ROS signaling pathway, in Ang II-induced cell proliferation. 66 The JAK/STAT pathway also possesses a crucial role in stem cell renewal; and its activation causes p38 phosphorylation and eventually, iPSCs differentiation into the target cell. 79 The effect of Ang II on ESC differentiation was also investigated. 80 The AT1 receptor activation stimulates collagen IV protein, which then induces ESC differentiation to SMCs. Collagen IV is one the extracellular matrix proteins having a role in cell adhesion, growth, differentiation and migration. 81 The PI3/Akt pathway, a downstream cascade activated by Ang II, is involved in ESC differentiation by mediating in the upregulation of several transcription factors, such as: egr-1, c-fos/c-jun, Stat91, NFk-B and the Krüppel-like zinc-finger (KLF5/BTEB2). [82] [83] [84] Out of all of them, NFk-B is significantly up-regulated in Ang II-treated cells, suggesting that there is NFk-B involvement in ESC differentiation into the SMSc. 1, 85 The TGF-β/Smad pathway possesses a fundamental role in the cellular responses to Ang II. Ang II stimulates TGF-β secretion in different tissues, such as fibroblasts and SMCs, that induce interstitial fibrosis in the heart and kidney. 86 Furthermore, the TGF-β/Smad 3 pathway is responsible for vascular fibrosis and arteriosclerosis. 87 The autocrine TGF-β/Smad pathway makes the differentiation of adipose tissue-derived MSCs to SMCs. The inactivation of the TGF-β receptor suppresses the expression of SMC markers such as calponin, h-caldesman and alpha-smooth muscle actin (SMA). 63 Besides, TGF-β secretion is associated with the MAPK/ERK pathway; and Ang II in this pathway interferes with TGF-β production, thus resulting in the differentiation of MSCs to SMCs. 88 As was previously mentioned, MSC transplantation has great importance, along with its various paracrine effects on CVD improvement. 89, 90 The supportive effects of vascular endothelial growth factor (VEGF) have been identified in the migration, invasion of extracellular matrix, proliferation and survival of MSCs; and they contribute to MSCs' paracrine effects; 88, 91, 92 hence, all pathways increasing VEGF will arise the function of MSCs. Ang II enhances VEGF mRNA and protein expression in MSCs, 93 which contributes to the Akt signaling pathway. Ang II is itself associated with Akt signaling pathway activation. 94, 95 Pretreatment of MSCs with the Akt inhibitor LY292002 decreases Ang II-induced VEGF expression. Therefore, local Ang II, as a cytokine, may enhance VEGF production in MSC grafts and upgrade the transplantation efficacy.
The role of vascular endothelium in CVD is wellknown, but adult endothelial cells have limited regeneration capacity. EPCs are responsible for consistent recovery of endothelium after injury and participate in angiogenesis. 96 CVDs are related to both the decrease of EPC mobilization and the number of EPCs present in the injured site. Regarding the pathobiology of CVDs, the role of RAS is proved to be effective in EPC function. 97 The angiogenic function of Ang II stimulates recruitment of EPCs to ischemic regions and starts vascularization, through VEGF-induced endothelial nitric oxide synthase (eNOS). 98 Moreover, Ang II induces EPC proliferation via a VEGFmediated signaling pathway. 99 The formation of NADPH and ROS constitute the stimulatory effects of Ang II on EPCs, which is necessary for normal EPC physiological function, but causes cell senescence in the long term. 100 The main mechanisms of cell senescence are related to the oxidative stress induction and ROS/pyroxynitrite in longterm exposure to the Ang II in EPCs. 101 Acute high-dose exposure to Ang II, similar to chronic exposure, also negatively affects EPCs; as in the hind limb ischemic rat model (Ang II infusion decreases the EPC cell population and its angiogenic function). 102 
The role of RAS inhibition in cardiac stem cells
The excess RAS generation is detected in CVDs such as heart failure, myocardial infarction, hypertension and atherosclerosis. 103 The RAS inhibitors, including ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have been widely studied in CVDs beyond their impact in lowering the blood pressure. 104 In spite of the increased use of stem cell therapy in regenerative medicine, these cells' engraftment, improvements and the evaluation of their functional properties are insufficient in clinical trials/ animal models 105, 106 ; hence, clarifying the mechanisms that elevate the graft efficacy seems important.
Some researchers evaluated the impact of RAS inhibitors on stem cell therapy in the cardiovascular system. 107 MSCs express both AT1 and AT2 receptors. Ang II induces VEGF secretion in MSCs through phosphorylation of Ser473Akt, which are transplanted into the gastronomies muscle and thus, increases blood flow. Valsartan, an ARB, inhibits VEGF release; and therefore, angiogenesis in vivo. 108 The IGF-1secreted from stem cells has a close relationship with the RAS and down-regulate the local RAS through the attenuation of the p53 gene. 109 The IGF-1 has an anti-apoptotic effect on cardiomyocytes in ischemic heart disease and also enhances differentiation and survival of stem cells after transplantation. 110 In acute MI in cardiomyocytes, ACEIs upregulate the IGF-1 receptors; thus, the concurrent use of perindopril in bone marrow stem cell transplantation increases the paracrine effects of the IGF-1, which abolishes apoptosis through increased Bcl2 expression and improves cardiac function. 111 Also, pre-treatment of MSCs with ARBs before transplantation increases their trans-differentiation efficacy and also improves the systolic function of the heart. 112 EPCs are up-regulated during acute ischemia, while they are down-regulated in atherosclerosis, stable coronary artery disease and Type 2 diabetes mellitus. As mentioned above, Ang II is effective in the recruitment of EPCs to ischemic regions. 113, 114 The stimulation of the proliferation in circulating EPCs and increasing of their population is a new strategy for prevention and treatment of ischemic heart disease. The initial observations, linked to the ARBs' role in increasing the EPC population, were reported in Type 2 diabetes mellitus patients whom were treated with olmesartan and irbesartan for 2 weeks. 115 In addition, irbesartan in hyperchlostrelomic hamsters elevates the number of circulating EPCs and suppresses plaque formation in atherosclerosis, via inhibition of pro-inflammatory factors. 116 A decrease in the number of circulating EPCs is one of the reasons for impaired vasculogenesis and reduced blood flow in Type 2 diabetes mellitus patients. 117 In longterm use and an escalation of dose, Valsartan increases circulating EPCs in diabetic patients with asymptomatic coronary artery disease. 118 The exact underlying mechanism remains to be elucidated, but suppression of oxidative stress might be one possible hypothesis of valsartan function. 119 ARBs also increase the EPC population in hypertensive patients. Cell redox balance is a regulator of self-renewal and differentiation in stem cell/progenitor cells, and antioxidants help preserving their function. 120 ARBs can improve EPC dysfunction by reducing oxidative stress. 121 In clinical studies ramipiril, an ACEI, increases the number and the function of the EPCs without affecting blood pressure. 122 Telmisartan has a beneficial effect on the number of circulating EPC in normotensive patients with coronary artery disease. 123 The oxidative stress also diminishes the half-life of circulating EPCs, thus blocking of the ROS by ARBs extends their life. 124 The local RAS is associated with oxidative stress in the cardiovascular system. In precursor cells, Ang II and its oxidative stress signaling cause cardiac cell death. 125 Besides, inhibiting the NADPH oxidase via ARBs and their antioxidant effects generate vasoprotective effects. 124 Candesartan increases EPC colonies in colony-forming unit assays, in spontaneously hypertensive rats. Down-regulation of NADPH oxidase and the reduction of the thiobarbitoric acid-reactive substance (TRABS) score demonstrate the candesartan effects through its antioxidant mechanism. 126 Lowering blood pressure in 90% of hypertensive patients with ARBs without any connection to plasma renin function indicates the pathogenesis of primary hypertension, which is related to tissue angiotensin. 127 Losartan increases both the number and the migration of the EPCs that are augmented in pretreatment with tempol, suggesting the antioxidant pathway of the drug. 127 Cell-derived micro-particles (MPs) have been a matter of interest, due to their essential role in vascular homeostasis in various physiologic and pathologic processes. Platelets, blood cells and endothelium are the MP source. 128 MPs are the atherosclerosis markers and they increase during the disease, compared to EPCs. Irbesartan not only performs beneficial effects on the number, function, engraftment efficacy and the survival of EPCs; but also decreases MPs. 129 Some ARBs, such as telmisartan, are peroxisome proliferator-activated receptor gamma (PPAR-γ) ligands. 130 Upon finding that thiazolidonediones (PPAR-γ agonists) reduce vascular inflammation and stimulate neo-vasculogenesis in the cerebral ischemic model, it is possible that ARBs that are PPAR-γ agonists could be effective in this context. Telmisartan induces adiponectin secretion via a PPAR-γ activation mechanism. 131, 132 Adiponectin, an antiatherogenic adipo-cytokine, induces angiogenesis in different in vivo and in vitro models. 133 Besides that, telmisartan increases the proliferation of EPCs derived from blood by the PI3/Akt signaling pathway. Findings in a Β-gal-staining study indicate that telmisartan in high doses can upregulate Akt-mediated p53 that is involved in cell senescence. 131 
Conclusion
In summary, regenerative progenitor cell therapy has emerged as a possible alternative for pharmacotherapy in CVD patients. In order to improve the efficiency of regenerative medicine, researchers investigated the effect of the modulation of various cell-signaling pathways, including the RAS. Effects of Ang II in stem cell proliferation and differentiation have been documented in the literature. The presence of the RAS components in progenitor cells and the cardiovascular tissue may regulate growth and development; and thus, may contribute to preparation of cardiovascular progenitor cells for clinical transplantation. Pharmacotherapy by means of ARBs or ACEIs that affect cell-signaling mechanisms is a potential therapeutic intervention.
